James J Kim

US Patent:

20090282741, Nov 19, 2009

Filed:

May 16, 2008

Appl. No.:

12/122022

Inventors:

James S. Kim - Carrollton TX, US

International Classification:

E06B 7/18

US Classification:

49383

Abstract:

A protective device which closes and seals the gap which forms between a pivotally mounted door and its jamb. The protective device generally spans the door and jamb, and occupies and generally does not extend outside the gap. The protective device may include an elastic or resilient or expansive material or member, and a fastener securing the protective device at a selected orientation relative to

US Patent:

20110214355, Sep 8, 2011

Filed:

Oct 27, 2010

Appl. No.:

12/913269

Inventors:

James S. Kim - Carrollton TX, US

International Classification:

E05D 11/00

US Classification:

49383, 16223

Abstract:

A protective device which closes and seals the gap which forms between a pivotally mounted door and its jamb. The protective device generally spans the door and jamb, and occupies and generally does not extend outside the gap. The protective device may include an elastic or resilient or expansive material or member, and a fastener securing the protective device in place relative to the door and the jamb.

US Patent:

20200181226, Jun 11, 2020

Filed:

Jan 30, 2018

Appl. No.:

16/481786

Inventors:

- Cambridge MA, US
Gregory MOTZ - Cambridge MA, US
Michael FRAY - Cambridge MA, US
Birgit SCHULTES - Cambridge MA, US
James HEMPHILL - Cambridge MA, US
James KIM - Cambridge MA, US
Tooba CHEEMA - Cambridge MA, US
Taylor HICKMAN - Cambridge MA, US

Assignee:

UNUM THERAPEUTICS INC. - Cambridge MA

International Classification:

C07K 14/725
C07K 16/28
A61K 39/395
C07K 14/705
C07K 14/735
A61P 35/00
C12N 5/0783
A61K 45/06

Abstract:

Disclosed herein are antibody-coupled T cell receptor (ACTR) polypeptides comprising: a CD16A extracellular domain, a transmembrane domain, one or more co-stimulatory signaling domains, at least one of which is a CD28 co-stimulatory signaling domain, and a CD3z cytoplasmic signaling domain. Also disclosed herein are genetically engineered immune cells, expressing: a first polypeptide which is an antibody-coupled T cell receptor (ACTR); and a second polypeptide that elicits a co-stimulatory signal as well as methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic antibody and an effective amount of immune cells (e.g., T lymphocytes and/or NK cells) expressing an antibody-coupled T-cell receptor (ACTR) polypeptide.